The Global Scopolamine Market Growth Accelerated By Rising Demand In Recurring Motion Sickness

Scopolamine is an alkaloid used as pharmaceutical drug primarily prescribed for preventing motion sickness or nausea related to anesthesia and surgery. Scopolamine patches or sublingual tablets are used to treat nausea and vomiting associated with recurring motion sickness especially during travel via ships, boats or planes.

The global Scopolamine Market is estimated to be valued at US$ 3676.85 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The growing adoption of scopolamine patches and sublingual tablets to prevent motion sickness during frequent travel has been a key factor propelling the growth of scopolamine market. Rising disposable income and increasing tourism activities have contributed to rising incidence of motion sickness necessitating preventive treatment using scopolamine-based pharmaceutical products. With evolving lifestyle and engagement in regular recreational and occupational activities involving mode of transport prone to induce motion sickness, the demand for scopolamine drugs is expected to grow substantially over the forecast period. Furthermore, ongoing R&D focused on developing novel drug delivery systems is anticipated to provide new opportunities for market players in the years to come.

Segment Analysis
The global scopolamine market is segmented by source, distribution channel, application, and geography. By source, the bark derived scopolamine sub-segment currently dominates the market owing to established supply chain and availability. By distribution channel, the retail pharmacy sub-segment holds the largest market share due to ease of accessibility and affordability. By application, the gastrointestinal disorders sub-segment accounts for more than 35% of the market share due to growing prevalence of gastrointestinal issues worldwide.

Key Takeaways
The global Scopolamine Market Growth  is expected to witness high growth over the forecast period of 2023 to 2030. The global Scopolamine Market is estimated to be valued at US$ 3676.85 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.

The global scopolamine market is expected to witness high growth over the forecast period. Regional analysis related content comprises North America currently dominates the global scopolamine market with over 40% share due to well-established healthcare infrastructure and rising R&D investments in drug development.

Key players related content comprises Key players operating in the scopolamine market are Baxter International Inc., GlaxoSmithKline plc, Novartis AG, Perrigo Company plc, Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD.

For more insights, read- https://www.ukwebwire.com/scopolamine-market-trends-size-and-share-analysis-2/